Moderna vaccine, Genentech obesity deal, Trump’s FDA pick — a BioCentury podcast

• Personalized cancer vaccines — A Phase III melanoma win gives Moderna and Merck important validation for mRNA neoantigen vaccines and raises the prospect of a new oncology treatment modality, but key questions remain about durability, scalability, cost, reimbursement, and applicability beyond PD-1-responsive tumors

• Roche’s obesity strategy — Roche and Genentech's Hanmi deal adds a potential first-in-class urocortin 2 asset designed to reduce fat while sparing lean mass, underscoring how large companies are diversifying beyond GLP-1s to build next-generation combination obesity franchises...